A Phase 2 Randomised, Double Blind Clinical Trial Assessing the Tolerability of two Different Rations of Medicinal Cannabis in Patients with Glioblastoma Multiforme (GMB) Project Lead Investigator: Dr Janet Schloss This world first clinical trial investigating whether medicinal cannabis can benefit patients with malignant brain tumours is being led by Clinical Trials Manager Dr Janet Schloss from the Office of Research and supported by internationally renowned neurosurgeon Professor Charlie Teo. Based on recent studies, medicinal cannabis may slow the growth of tumours particularly aggressive gliomas, as such it is essential to conduct further clinical research in this area. Investigating the appropriate dosage guidelines and understanding whether medicinal cannabis has a role to play in reducing tumour size and the development of new glioma tumours for patients is imperative. Assessing this area could be life changing for individuals living with the disease and their families. This phase 2 clinical trial will examine whether high THC medicinal cannabis can be tolerated by people with glioma (a type of brain tumour) and if it can affect tumour growth when administered with standard medical treatment. This trial is funded by BioCeuticals, Australia's leading provider of nutritional and therapeutic supplements, who have invested $500,000 as part of their commitment to provide practitioners with evidence-based solutions for health conditions.